Evidence map›Paper›PMID 42814151›Full record

ArticleDiabetologia2026

Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.

Suyeon Kim, Hwa Yeon Ko, Bin Hong, Ju Hwan Kim, Sungho Bea, Jae Hyun Bae, Young Min Cho, Yoosoo Chang, Christopher D Byrne, Ju-Young Shin

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Suyeon KimSchool of Pharmacy, Sungkyunkwan University, Suwon, South Korea.ORCID http://orcid.org/0009-0009-9364-3665
Hwa Yeon KoSchool of Pharmacy, Sungkyunkwan University, Suwon, South Korea.ORCID http://orcid.org/0000-0001-5297-8826
Bin HongSchool of Pharmacy, Sungkyunkwan University, Suwon, South Korea.ORCID http://orcid.org/0000-0002-9668-2602
Ju Hwan KimSchool of Pharmacy, Sungkyunkwan University, Suwon, South Korea.ORCID http://orcid.org/0000-0001-7253-6515
Sungho BeaDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2622-6553
Jae Hyun BaeDivision of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.ORCID http://orcid.org/0000-0002-1384-6123
Young Min ChoDivision of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.ORCID http://orcid.org/0000-0002-2331-6126
Yoosoo ChangCenter for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0002-6945-9050
Christopher D ByrneNutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0001-6322-7753
Ju-Young ShinCollege of Pharmacy, Seoul National University, Seoul, South Korea. shin.jy@snu.ac.kr.ORCID http://orcid.org/0000-0003-1010-7525

Funding

Patient-Centered Clinical Research Coordinating Center (PACEN) RS-2025-02215225
6 · The paper itself

Abstract

aims/hypothesisWhile both empagliflozin and dapagliflozin are known to improve hepatic steatosis and liver enzyme levels, robust phase 3 trial evidence for improving steatohepatitis and fibrosis is currently exclusive to dapagliflozin. Therefore, a head-to-head comparison between two agents is warranted, to compare the hepatic outcomes between empagliflozin and dapagliflozin in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

methodsUsing nationwide Korean claims data, we constructed a new-user cohort of adults with MASLD, defined as having type 2 diabetes and a fatty liver index (FLI) ≥60, who initiated empagliflozin or dapagliflozin between May 2016 and December 2023. Outcomes of interest were FLI-defined MASLD regression (achieving FLI <30) and decompensated hepatic events (ascites, variceal bleeding, hepatic failure, liver transplantation). After 1:1 propensity score matching, HRs and 95% CIs were estimated using Cox models.

resultsAmong 265,098 new users of empagliflozin and dapagliflozin, 101,487 pairs were 1:1 propensity score-matched (mean age 54.3 years; male 71.3%). Compared with dapagliflozin, empagliflozin was associated with a marginally higher likelihood of FLI-defined MASLD regression (HR 1.06; 95% CI 1.00, 1.11). The risk of decompensated hepatic events was comparable (HR 0.99; 95% CI 0.94, 1.03). Dose-stratified analyses yielded consistent findings in both FLI-defined MASLD regression (low-dose: HR 1.19; 95% CI 0.77, 1.83; high-dose: 1.14; 1.01, 1.28) and decompensated hepatic events (low-dose: 0.95; 0.74, 1.23; high-dose: 1.04; 0.93, 1.15). CONCLUSIONS/

interpretationAmong individuals with MASLD, no significant differences were observed between empagliflozin and dapagliflozin in the risk of decompensated hepatic events.

Indexed as

Metabolic dysfunction-associated steatotic liver disease (MASLD)PharmacoepidemiologySodium–glucose cotransporter 2 inhibitorsType 2 diabetes

Identifiers

PMID42814151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.